Table 3.

Current and recent perioperative chemotherapy phase III trials for MIBC

Institution	Regimen	Setting	Status/Results	Trial ID
University Hospital, Rouen	HD-MVAC vs. GC	Neoadjuvant or Adjuvant	Recruiting participants.	NCT01812369
Southwest Oncology Group	DD-MVAC vs. GC	Neoadjuvant	Recruiting participants [21].
Japan Clinical Oncology Group	MVAC vs. Immediate RC	Neoadjuvant	Completed. 130 total subjects. OS increased by 35% in MVAC arm (64 subjects) but was not statistically significant. Improved pT0 rate with MVAC [22].
FTRC	GC vs. Immediate RC	Adjuvant	Completed. 192 total subjects. No difference between adjuvant treatment (102) and control arms for 5 year OS. Failed to reach accrual goal, low study power [23].	NCT00054626
Cairo University	GC + radiotherapy vs. radiotherapy alone	Adjuvant	Completed. 146 total subjects. Improvement in 45-month DFS from 28% to 70% in chemoradiotheraphy (72) group but failed to be statistically significant [24].	NCT01734798
Eastern Cooperative Oncology Group	MVAC vs. PCa	Adjuvant	Completed. Results unreported.	NCT00003701
Sun Yat-Sen University	Intraarterial GC	Adjuvant	Recruiting Participants.	NCT01627197
Association of Urogenital Oncology	Adjuvant vs. Progression-Triggered Gemcitabine	Adjuvant	Completed. 114 total subjects. No statistically significant difference between adjuvant or progression-triggered Gemcitabine for DFS or OS. Failed to reach accrual goal [25].	NCT00146276
EORTC	Adjuvant vs. Progression Triggered MVAC + Gemcitabine	Adjuvant	Closed early due to poor accrual	NCT00028756

FTRC = Fondazione C.N.R./Regione Toscana “G. Monasterio”, Pisa, Italy. EORTC = European Organisation of Research and Treatment of Cancer. GC = Gemcitabine + Cisplatin. MVAC = Methotrexate + Vinblastine + Doxorubicin + Cisplatin. RC = Radical Cystectomy. PCa = Paclitaxel + Carboplatin. HD = High Dose. DD = Dose Dense. OS = Overall Survival. DFS = Disease Free Survival.